JP7665747B2 - ジヒドロピリダジン－３，５－ジオン誘導体の製造方法 - Google Patents

ジヒドロピリダジン－３，５－ジオン誘導体の製造方法 Download PDF

Info

Publication number
JP7665747B2
JP7665747B2 JP2023527885A JP2023527885A JP7665747B2 JP 7665747 B2 JP7665747 B2 JP 7665747B2 JP 2023527885 A JP2023527885 A JP 2023527885A JP 2023527885 A JP2023527885 A JP 2023527885A JP 7665747 B2 JP7665747 B2 JP 7665747B2
Authority
JP
Japan
Prior art keywords
formula
compound represented
powder
solvent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023527885A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022260062A1 (https=
Inventor
政利 村形
志央 小宮
増▲華▼ 侯
太郎 榎本
智嗣 谷田
弘志 福田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JPWO2022260062A1 publication Critical patent/JPWO2022260062A1/ja
Application granted granted Critical
Publication of JP7665747B2 publication Critical patent/JP7665747B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/001—General concepts, e.g. reviews, relating to catalyst systems and methods of making them, the concept being defined by a common material or method/theory
    • B01J2531/002—Materials
    • B01J2531/004—Ligands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84—Metals of the iron group
    • B01J2531/842—Iron
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Epidemiology (AREA)
JP2023527885A 2021-06-08 2022-06-08 ジヒドロピリダジン－３，５－ジオン誘導体の製造方法 Active JP7665747B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021096200 2021-06-08
JP2021096200 2021-06-08
PCT/JP2022/023068 WO2022260062A1 (ja) 2021-06-08 2022-06-08 ジヒドロピリダジン－３，５－ジオン誘導体の製造方法

Publications (2)

Publication Number Publication Date
JPWO2022260062A1 JPWO2022260062A1 (https=) 2022-12-15
JP7665747B2 true JP7665747B2 (ja) 2025-04-21

Family

ID=84426032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527885A Active JP7665747B2 (ja) 2021-06-08 2022-06-08 ジヒドロピリダジン－３，５－ジオン誘導体の製造方法

Country Status (13)

Country Link
US (1) US20250115585A1 (https=)
EP (1) EP4353718A4 (https=)
JP (1) JP7665747B2 (https=)
KR (1) KR20240019168A (https=)
CN (1) CN117460727A (https=)
AR (1) AR126060A1 (https=)
AU (1) AU2022291310A1 (https=)
BR (1) BR112023023841A2 (https=)
CA (1) CA3221272A1 (https=)
IL (1) IL309054A (https=)
MX (1) MX2023013898A (https=)
TW (1) TW202313590A (https=)
WO (1) WO2022260062A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142273A1 (ja) 2013-03-13 2014-09-18 中外製薬株式会社 ジヒドロピリダジン－３，５－ジオン誘導体
WO2016039458A1 (ja) 2014-09-12 2016-03-17 中外製薬株式会社 ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2525659B1 (en) * 2010-01-19 2019-02-27 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
CN102869656B (zh) 2010-04-28 2014-03-12 安斯泰来制药株式会社 四氢苯并噻吩化合物
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
KR101941048B1 (ko) 2011-10-27 2019-01-22 아스텔라스세이야쿠 가부시키가이샤 아미노 알킬 치환 n-티에닐벤즈아미드 유도체
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
DE102013111551B3 (de) 2013-10-21 2015-01-22 Wago Verwaltungsgesellschaft Mbh Tragschienengehäuse
US10934280B2 (en) 2016-08-15 2021-03-02 Eli Lilly And Company Condensed thiophene derivatives useful as NaPi-IIb inhibitors
CN111801335A (zh) 2018-01-17 2020-10-20 株式会社神钢环境舒立净 亚硼酸酯化合物的合成方法、亚硼酸酯化合物的钠盐及其合成方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142273A1 (ja) 2013-03-13 2014-09-18 中外製薬株式会社 ジヒドロピリダジン－３，５－ジオン誘導体
WO2016039458A1 (ja) 2014-09-12 2016-03-17 中外製薬株式会社 ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TSUBOI Yoshinorim et al.，EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidne，Kidney International，2020年，Vol.98(2)，p.343-354
第十六改正 日本薬局方，2011年，pp.64-68,2070

Also Published As

Publication number Publication date
EP4353718A1 (en) 2024-04-17
BR112023023841A2 (pt) 2024-01-30
EP4353718A4 (en) 2025-11-05
US20250115585A1 (en) 2025-04-10
IL309054A (en) 2024-02-01
CN117460727A (zh) 2024-01-26
MX2023013898A (es) 2023-12-11
WO2022260062A1 (ja) 2022-12-15
CA3221272A1 (en) 2022-12-15
AU2022291310A1 (en) 2024-01-18
JPWO2022260062A1 (https=) 2022-12-15
KR20240019168A (ko) 2024-02-14
TW202313590A (zh) 2023-04-01
AR126060A1 (es) 2023-09-06

Similar Documents

Publication Publication Date Title
JP6761448B2 (ja) アザインドールを作製するための方法および中間体
JP2019038809A (ja) ７−シクロペンチル−２−（５−ピペラジン−１−イル−ピリジン−２−イルアミノ）−７ｈ−ピロロ［２，３−ｄ］ピリミジン−６−カルボン酸ジメチルアミドの塩およびその製造方法
TW200404786A (en) Chemical process
JP6894917B2 (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
JP2008543974A (ja) ペメトレキセド二酸の結晶形およびその調製方法
JP7292501B2 (ja) Ｃｄ７３阻害剤の結晶形態
JP2023544775A (ja) ７－クロロ－６－フルオロ－１－（２－イソプロピル－４－メチルピリジン－３－イル）ピリド［２，３－ｄ］ピリミジン－２，４（１Ｈ，３Ｈ）－ジオンのアトロプ異性体をラセミ化及び単離するためのプロセス
JP6779972B2 (ja) 呼吸器合胞体ウイルス（ｒｓｖ）感染症の処置のためのｎ−［（３−アミノ−３−オキセタニル）メチル］−２−（２，３−ジヒドロ−１，１−ジオキシド−１，４−ベンゾチアゼピン−４（５ｈ）−イル）−６−メチル−４−キナゾリンアミンの結晶形
JP2019521190A (ja) 二メシル酸パルボシクリブの固体形態
JP7665747B2 (ja) ジヒドロピリダジン－３，５－ジオン誘導体の製造方法
WO2003092889A1 (en) Process for the preparation of 2-aminopyrazine derivatives
JP7149980B2 (ja) ピリド［３，４－ｄ］ピリミジン誘導体又はその溶媒和物の結晶
HK40103591A (zh) 二氢哒嗪-3，5-二酮衍生物的制造方法
JP2010254692A (ja) パリペリドンの精製方法
EA052755B1 (ru) Способ получения производного дигидропиридазин-3,5-диона
EA051007B1 (ru) Способ получения производного дигидропиридазин-3,5-диона
JP6289619B2 (ja) ピリジン誘導体の新規な結晶多形体およびその製造方法
AU2005230922A1 (en) Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-B:2',3'-E][1,4]diazepin-6-one
TW202530185A (zh) 芳基醯胺衍生物的製造方法
JP2017206445A (ja) 呼吸器疾患の治療及び／又は予防のための医薬組成物
HK40011691B (en) Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
HK40011691A (en) Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
CN1216541A (zh) 具有aⅱ拮抗活性的n－3取代嘧啶－4－酮
CN101405290A (zh) 右佐匹克隆苹果酸盐的多晶型物
HK1159095A (en) Synthesis and novel salt forms of (r)-5-(e)-2-(pyrrolidin-3-ylvinyl)pyrimidine

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240527

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250409

R150 Certificate of patent or registration of utility model

Ref document number: 7665747

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150